İzole tavşan böbreğinde, Endotelin 1`in böbrek perfüzyon basıncında, idrar hacminde ve böbrek ağırlığında oluşturduğu değişiklikler üzerinde stabil prostasiklin analoğu iloprostun etkisi ve bu etkide cAMP`nin rolü
Başlık çevirisi mevcut değil.
- Tez No: 48693
- Danışmanlar: PROF.DR. HAKAN ZENGİL
- Tez Türü: Doktora
- Konular: Eczacılık ve Farmakoloji, Pharmacy and Pharmacology
- Anahtar Kelimeler: Böbrek, Endotelinler, Epoprostenol, İloprost, Kidney, Endothelins, Epoprostenol, Iloprost
- Yıl: 1996
- Dil: Türkçe
- Üniversite: Gazi Üniversitesi
- Enstitü: Sağlık Bilimleri Enstitüsü
- Ana Bilim Dalı: Belirtilmemiş.
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: Belirtilmemiş.
Özet
-44- 8.İNGİLİZCE ÖZET: Endothelin-1 (ET-1) and prostacyclin (PGI2) are the mediators, released from endothelium, cause an opposite effect on vascular smooth muscle. While ET-1 induces vasoconstriction, PGI2 causes vasodilatory effect. Therefore it can be assumed that there might be an interaction between these mediators. This study was undertaken to investigate the effect of lloprost (ILO), a stable analogue of PGI2, on the responses to ET-1 and the role of cAMP in this interaction in the isolated perfused rabbit kidney. ET-1 at the dose of 10"9 M caused an increase (9.86 ± 0.98 mmHg, n=13) and ILO (200 ng/ml) alone induced a decrease (2.29 ± 0.30 mmHg, n=13) in the perfusion pressure. ET-1 when used together with ILO causes an increase in perfussion pressure but this increase is found to be reduced when compared with ET-1 (4.94 ± 1.14 mmHg, n=13) (p<0.001). ET-1 caused an insignificant reduction in urine outflow. But ILO alone and ET-1+ILO together caused a significant reduction (p<0.05). Perfusion of ET-1, ILO and ET-1+ILO respectively caused a marked increase in kidney weights (before experiment: 13.57 ± 0.50 gr, after experiment: 14.99 ± 0.43 gr, n=5) (p<0.05). In perfusions of theophylline, ET-1, ILO or ET-1+ILO alone did not make any alteration in kidney weight. cAMP levels were found to be reduced in ET-1+ILO administered group (Control: 1300.67 ± 130.85 pmol/gr kidney, ET-1+ILO: 1114 ± 111.61 pmol/gr kidney, n=3) (p<0.05) while did not change in ET-1 or ILO alone applied groups. In conclusion; It was assumed that PGI2 plays a mediator role in response to ET-1 but cAMP as a second messenger didn't participitate this interaction.-43- cAMP ölçümlerinde ise ET-1, ILO uygulanan böbreklerle kontrol böbrekler arasında anlamlı bir konsatrasyon farkı gözlenmemiştir. ET-1+İLO uygulanan böbreklerde ise kontrollara göre azalmış olduğu görüldü (p<0.05). Sonuç olarak, ET'nin cevaplarında PGfe' nin mediator rol oynadığı fakat bu etkileşimde cAMP'nin aracılık etmediği düşünülmüştür.
Özet (Çeviri)
-44- 8.İNGİLİZCE ÖZET: Endothelin-1 (ET-1) and prostacyclin (PGI2) are the mediators, released from endothelium, cause an opposite effect on vascular smooth muscle. While ET-1 induces vasoconstriction, PGI2 causes vasodilatory effect. Therefore it can be assumed that there might be an interaction between these mediators. This study was undertaken to investigate the effect of lloprost (ILO), a stable analogue of PGI2, on the responses to ET-1 and the role of cAMP in this interaction in the isolated perfused rabbit kidney. ET-1 at the dose of 10"9 M caused an increase (9.86 ± 0.98 mmHg, n=13) and ILO (200 ng/ml) alone induced a decrease (2.29 ± 0.30 mmHg, n=13) in the perfusion pressure. ET-1 when used together with ILO causes an increase in perfussion pressure but this increase is found to be reduced when compared with ET-1 (4.94 ± 1.14 mmHg, n=13) (p<0.001). ET-1 caused an insignificant reduction in urine outflow. But ILO alone and ET-1+ILO together caused a significant reduction (p<0.05). Perfusion of ET-1, ILO and ET-1+ILO respectively caused a marked increase in kidney weights (before experiment: 13.57 ± 0.50 gr, after experiment: 14.99 ± 0.43 gr, n=5) (p<0.05). In perfusions of theophylline, ET-1, ILO or ET-1+ILO alone did not make any alteration in kidney weight. cAMP levels were found to be reduced in ET-1+ILO administered group (Control: 1300.67 ± 130.85 pmol/gr kidney, ET-1+ILO: 1114 ± 111.61 pmol/gr kidney, n=3) (p<0.05) while did not change in ET-1 or ILO alone applied groups. In conclusion; It was assumed that PGI2 plays a mediator role in response to ET-1 but cAMP as a second messenger didn't participitate this interaction.
Benzer Tezler
- İzole tavşan böbreğinde in vivo ve in vitro iskemi-reperfüzyonun farklı agonist yanıtlarında oluşturduğu değişiklikler ve bu yanıtlar üzerine platelet aktive edici faktör (PAF) reseptör antagonisti BN 52021...
The Changes induced by ischemia-reperfusion in responses to different agonists and the effect of BN 52021, platelet activating factor (PAF) receptor antagonist, in rabbit kidney
CANAN ULUOĞLU
Doktora
Türkçe
1998
Eczacılık ve FarmakolojiGazi ÜniversitesiFarmakoloji Ana Bilim Dalı
PROF. DR. ÖZENÇ TİMLİOĞLU
- İzole tavşan böbreğinde endojen ve eksojen platelet aktive edici faktörün noradrenalin ve endotelin-1 aracılı yanıtlar üzerine etkisi
The Effect of endogenous and exogenous platelet-activating factor on noradrenaline and endothelin-1 response in the isolated rabbit kidney
MERAL KAMU GÜLER
Tıpta Uzmanlık
Türkçe
2001
Eczacılık ve FarmakolojiGazi ÜniversitesiFarmakoloji Ana Bilim Dalı
PROF.DR. ÖZENÇ TİMLİOĞLU
- Tavşanlarda deneysel olarak geliştirilen akut renal yetmezlikte EDRF aktivitesindeki değişiklik ve Allopurinol`ün etkisi
Başlık çevirisi yok
MERAL ERDİNÇ
Doktora
Türkçe
1995
Eczacılık ve FarmakolojiDicle ÜniversitesiFarmakoloji Ana Bilim Dalı
DOÇ.DR. GÜNER ULAK
- İzole perfüze tavşan böbreğinde Endotelin Konverting Enzim İnhibisyonu`nun değişik agonist cevaplarına etkisi
The Effect of endothelin converting enzyme inhibition on the several agonist responses in the isolated perfused rabbit kidney
AYHAN SUCAK
- İzole perfüze tavşan böbreğinde endotelin reseptör antagonistlerinin çeşitli agonist yanıtları üzerindeki etkisi
The Effects of endothelin receptor antagonists on the responses to various agonists in the isolated perfused rabbit kidney
MEHTAP KILINÇ ÖZKUR
Doktora
Türkçe
1997
Eczacılık ve FarmakolojiGazi ÜniversitesiFarmakoloji Ana Bilim Dalı
PROF. DR. Z. SEVİM ERCAN